Summary

Overview
Global Generalized Myasthenia Gravis Treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
Myasthenia gravis is an antibody-mediated autoimmune condition impacting the function of the neuromuscular junction, directing to the fluctuating weakness of ocular, facial, bulbar, limb, and respiratory muscles. The condition has an assessed preponderance of 70-300 per million individuals globally. Unchecked myasthenia gravis can lead to considerable disability and recurrent infirmary admissions, with an assessed mortality rate of approximately 2%.
Although a considerable number of individuals with myasthenia gravis advantage from typical therapies, including cholinesterase inhibitors, corticosteroids, and steroid-sparing immunosuppressants (e.g., azathioprine and mycophenolate mofetil), around 8.5-15% of individuals still hold differing extents of disability because of insufficiently controlled clinical manifestation or inappropriate side effects.
The growing cases, increasing product authorizations, positive outcomes from research activities, market developments including mergers, acquisitions, product introductions, growing awareness among other factors are expected to boost the global generalized myasthenia gravis treatment market growth in the forecast period. Further, increasing research activities, investments and fundings are also expected to contribute to the global market growth in the forecast period.
Dynamics
Increasing Drug Authorizations
The drug authorizations from distinct regulatory bodies are expected to boost the global market growth during the forecast period. For instance, in June 2023, UCB, a multinational biopharmaceutical corporation, obtained the U.S. Food and Drug Administration (FDA) authorization for its RYSTIGGO (rozanolixizumab-noli) indicated for the treatment of generalized myasthenia gravis (gMG) in adult individuals who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
The authorization is established on the pivotal Phase 3 MycarinG investigation in gMG2, an extensive phase 3 investigation which showed treatment with rozanolixizumab-noli resulted in statistically noteworthy advancements in gMG-specific results, including day-to-day movements including breathing, speaking, ingesting, and being capable of rising from a chair.
Moreover, in March 2023, argenx, a multinational immunology corporation dedicated to enhancing the lives of individuals with intense autoimmune conditions, obtained the UK Medicines and Healthcare Products Regulatory Agency (MHRA) authorization for its VYVGART (efgartigimod alfa-fcab) as an add-on to traditional therapy for the treatment of adult patients with gMG that are AChR antibody positive.
Growing Support Funding and Awareness
The growing support funding and awareness about the myasthenia gravisare also expected to boost the global market growth during the forecast period. For instance, in February 2023, the Muscular Dystrophy Association (MDA) declared the five organizations accepting $109,065 in grant funding the grants are intended to advance and support MDA's key general approach and advocacy initiatives in coordination with awardees to allocate individuals living with neuromuscular disorders to live longer better independent lives.
In the temperament of MDA's dedication to the association, the community is using this funding agenda to promote impactful and cooperative advocacy schemes and initiatives. Grantees in this ingenious model include All Wheels Up, Cure CMD, Cure Rare Disease, OPMD Association, and Tufts Medical Center (Dr. James Chambers and team).
Further, in February 2022, in recognition of Rare Disease Day and the 25-30 million Americans living with rare conditions, the Janssen Pharmaceutical Companies of Johnson & Johnson launched the restored iMaGineMyMG, a nationwide movement that strived to raise awareness of myasthenia gravis (MG), a chronic autoimmune neuromuscular condition, and deliver aid to individuals living with the disorder. As part of the campaign, individuals impacted by MG are also expected to have access to iMaGineMyMG.com, a newly redesigned online aid planned to support and guide people throughout their journey with this rare condition.
High Drug Treatment Cost
The high cost of drug treatment is expected to hamper the global market growth during the forecast period. For instance, AstraZeneca's Soliris treatment costs over $650,000 annually before discounts, being one of the highly costly drugs in the U.S. After the Institute for Clinical and Economic Review (ICER) looked at the medicine's profile in Myasthenia gravis, the organization holds severe worries regarding its cost.
Moreover, according to studies, the mean per-patient yearly direct medical expense of illness was assessed at between $760 and $28,780, and the expense per hospitalization between $2550 and $164,730. The indirect expense of disease was assessed at $80 and $3550. Expenses differed extensively by patient features, and drivers of the immediate medical expense of disease-enclosed intravenous immunoglobulin and plasma exchange, myasthenic emergency, mechanical ventilatory aid, and hospitalizations..
Treatment Complications and Side Effects
The myasthenia gravis treatment complications such as long-term steroid effects like osteoporosis, hyperglycemia, cataracts, weight gain, hypertension, and avascular necrosis of the hip are expected to hamper the global myasthenia gravis treatment market growth during the forecast period. Moreover, the treatment has side effects such as chills, dizziness, headaches and fluid retention are also expected to hamper the global market growth during the forecast period.
Segment Analysis
The global generalized myasthenia gravis treatment market is segmented based on drug class, route of administration, distribution channel and region.
Monoclonal Antibody Drug Class Expected to Dominate Market
Owing to the increasing monoclonal antibody drug approvals and increasing number of approval request submissions the segment is expected to dominate the global market in the forecast period. For instance, in June 2023, the National Medical Products Administration (NMPA) of China accepted the Biologics License Application (BLA) of batoclimab (HBM9161) to treat generalized myasthenia gravis (gMG) from the Harbour Biomed, a multinational biopharmaceutical corporation committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology.
Moreover, in August 2023, Soliris (eculizumab) was authorized in Japan for extended usage to enclose the treatment of generalized myasthenia gravis (gMG) in pediatric individuals who are anti-acetylcholine receptor (AChR) antibody-positive and whose manifestations are hard to manage with elevated-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX).
Geographical Penetration
North America is Expected to Dominate the Global Market
Owing to the increasing market developments in North America the region is expected to dominate the global market in the forecast period. For instance, in May 2023, Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc., a privately owned, clinical-stage biotechnology corporation committed to promoting the next generation of antibody complement therapeutics, formed a merger agreement to unite the corporations in an all-stock transaction.
The merged company is expected to focus on growing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 presently in a Phase 1 clinical trial. Upon fulfillment of the coalition, the United corporation is anticipated to function under the name Dianthus Therapeutics, Inc. In backing of the coalition, Dianthus has confirmed affirmations for a $70 million private investment.
Furthermore, the positive support from government organizations for clinical investigations to advance the disease treatment is also expected to boost the regional market growth during the forecast period. For instance, according to the NIH press release in June 2023, the proof from a small-scale clinical investigation supported by a small business grant from the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, and funded by Cartesian Therapeutics, Gaithersburg, Maryland, indicates that a variation of the advanced blood cancer immunotherapy comprehended as CAR-T could be adjusted for the treatment of myasthenia gravis, an autoimmune condition of the nervous system. The altered CAR-T therapy, short for chimeric antigen receptor T-cell, utilized by scientists presents the potential for a longer-lasting decline in myasthenia gravis signs and was well-tolerated without substantial adverse effects.
COVID-19 Impact Analysis
Conclusions from a recent patient analysis, related to understandings from earlier registered patients, suggest that COVID-19 infection can boost the commencement of myasthenia gravis (MG). The conclusions, published in the Journal of Neurology, hypothesize that SARS-CoV-2 disease may have initiated thymic inflammation, spearheading the initial presentation of muscle-like epitopes and T-cell dysregulation.
With over a dozen of these patient investigations reported to date, the investigators emphasized the significance of additional case sequences that examine the pathological timeline and immunological aspects of MG induced by COVID-19. Thus, it is expected that COVID-19 has increased the demand for myasthenia gravis treatment during the pandemic.
By Drug Class
• Monoclonal Antibodies
• Corticosteroids
• Cholinesterase Inhibitors
• Immunosuppressants
• Others
By Route of Administration
• Injectable
• Oral
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In November 2022, CANbridge Pharmaceuticals, Inc., a multinational biopharmaceutical corporation, with a foundation in China, dedicated to the research, development, and commercialization of transformative treatments to treat rare disorders and oncology, obtained the Orphan Drug Designation by the United States Food and Drug Administration (FDA) for its CAN106, a clinical-stage recombinant humanized monoclonal antibody targeting C5 for the treatment of myasthenia gravis (MG).
• In September 2022, argenx SE, a multinational immunology corporation committed to improving the lives of individuals with severe autoimmune disorders, proposed a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SC efgartigimod (1000mg efgartigimod-PH20) for the therapy of generalized myasthenia gravis (gMG) in adult individuals.
• In April 2022, Grifols, a multinational leader in plasma-derived medicines assisting in enhancing individuals’ health and well-being for over 110 years, acquired 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German corporation that holds 89.88% of the standard shares and 1.08% of the preferred shares of Biotest AG, a European healthcare corporation specialized in creative hematology and clinical immunology.
Competitive Landscape
The major global players in the market include AstraZeneca, Astellas Pharma, F. Hoffmann-La Roche Ltd., Grifols, S.A., Argenx SE, UCB, Harbour Biomed, Lepu Medical Technology (Beijing)Co., Ltd., ALEXION PHARMACEUTICALS, INC., and Immunovant, Inc. among others.
Why Purchase the Report?
• To visualize the global generalized myasthenia gravis treatment market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of generalized myasthenia gravis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global generalized myasthenia gravis treatment market report would provide approximately 61 tables, 60 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents